{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:14:28Z","timestamp":1793466868952,"version":"4.5.0"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent chronic liver disorder, imposes a substantial global clinical and economic burden. Emerging evidence underscores inflammatory bowel disease (IBD) as a significant independent risk factor for MASLD. However, the global burden and trends of MASLD-IBD comorbidity remain largely obscured. This study aims to evaluate the global burden of MASLD-IBD from 1990 to 2021 and to project its trajectory to 2050. The findings will inform the development of proactive public health strategies<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Leveraging the Global Burden of Disease (GBD) 2021 database, we quantified IBD\u2019s contribution to MASLD via population-attributable fractions. We analyzed the global prevalence, mortality, and disability-adjusted life years (DALYs), stratifying by socio-demographic index (SDI), sex, and age. Estimated annual percentage change (EAPC) assessed 1990\u20132021 trends; Bayesian age-period-cohort modeling projected 2050 trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In 2021, the global age-standardized prevalence of MASLD-IBD comorbidity reached 171.7 cases (95% uncertainty interval [UI], 157.3\u2013187.1), with a corresponding DALY rate of 0.5 cases (95% UI, 0.4\u20130.6) per 10 million population. High-income regions, including North America, Australia, and Western Europe, bore the highest burden. From 1990 to 2021, 20 out of 21 GBD regions exhibited escalating age-standardized prevalence and DALY rates, most markedly in East Asia (prevalence EAPC = 3.18; 95% confidence interval [CI], 2.59\u20133.77) and East Europe (DALY EAPC = 4.05; 95% CI, 3.32\u20134.79). Middle SDI regions saw the largest absolute increases, with mortality mirroring DALY trends. Adults \u2265 60 years bore disproportionately higher burdens. By 2050, projections suggest divergent gender trends of rising female burden versus declining male rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>MASLD-IBD comorbidity burdens have risen globally over three decades, necessitating targeted interventions, particularly for ageing populations and high-risk regions. Gender-specific strategies will be critical for mitigating future impacts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003383","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T16:03:23Z","timestamp":1760457803000},"page":"1528-1542","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Global burden of MASLD-IBD comorbidity from 1990 to 2021 and trend prediction to 2050"],"prefix":"10.1097","volume":"112","author":[{"given":"Yuanshan","family":"Xu","sequence":"first","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youting","family":"Yi","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiankang","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyi","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fangshan Traditional Medical Hospital of Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyun","family":"Cui","sequence":"additional","affiliation":[{"name":"National Institute of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yi","family":"Wan","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"},{"name":"National Institute of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9716-0171","authenticated-orcid":false,"given":"Haiqiang","family":"Yao","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"},{"name":"National Institute of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Su","family":"Yuan","sequence":"additional","affiliation":[{"name":"Tang Center for Herbal Medicine Research, The University of Chicago, Chicago, IL, USA"},{"name":"Department of Anesthesia and Critical Care, The University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"R1-20260518","doi-asserted-by":"crossref","first-page":"1335\u201347","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"R2-20260518","doi-asserted-by":"crossref","first-page":"148\u201349","DOI":"10.1038\/s41575-025-01039-x","article-title":"MASLD as a non-communicable disease","volume":"22","author":"Sookoian","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20260518","doi-asserted-by":"crossref","first-page":"287\u201395","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201 807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"R4-20260518","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R5-20260518","doi-asserted-by":"crossref","first-page":"487\u2013503","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R6-20260518","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J Lipid Res"},{"key":"R7-20260518","doi-asserted-by":"crossref","first-page":"145\u201359","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R8-20260518","doi-asserted-by":"crossref","first-page":"531\u201344","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R9-20260518","doi-asserted-by":"crossref","first-page":"1822\u201330","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterol"},{"key":"R10-20260518","doi-asserted-by":"crossref","first-page":"1764\u201372","DOI":"10.1093\/ibd\/izz043","article-title":"Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"25","author":"Zou","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R11-20260518","doi-asserted-by":"crossref","first-page":"475\u201389","DOI":"10.1111\/liv.13265","article-title":"Hepatic manifestations of inflammatory bowel diseases","volume":"37","author":"Restellini","year":"2017","journal-title":"Liver Int"},{"key":"R12-20260518","doi-asserted-by":"crossref","first-page":"73\u201384","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R13-20260518","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s10620-017-4552-8","article-title":"Increased prevalence of NAFLD in IBD patients","volume":"62","author":"Gaidos","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R14-20260518","doi-asserted-by":"crossref","first-page":"4344905","DOI":"10.1155\/2022\/4344905","article-title":"Glucocorticosteroids and the risk of NAFLD in inflammatory bowel disease","volume":"2022","author":"Jarmakiewicz-Czaja","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R15-20260518","doi-asserted-by":"crossref","first-page":"39\u201349","DOI":"10.1038\/nrgastro.2017.136","article-title":"Environmental triggers in IBD: a review of progress and evidence","volume":"15","author":"Ananthakrishnan","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R16-20260518","doi-asserted-by":"crossref","first-page":"655\u201362","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases","volume":"569","author":"Lloyd-Price","year":"2019","journal-title":"Nature"},{"key":"R17-20260518","doi-asserted-by":"crossref","first-page":"360\u201373","DOI":"10.1007\/s13238-020-00814-7","article-title":"The role of the gut microbiome and its metabolites in metabolic diseases","volume":"12","author":"Wu","year":"2021","journal-title":"Protein Cell"},{"key":"R18-20260518","doi-asserted-by":"crossref","first-page":"764\u201377","DOI":"10.1016\/j.jhep.2023.12.024","article-title":"Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8(+) T cells","volume":"80","author":"Zheng","year":"2024","journal-title":"J Hepatol"},{"key":"R19-20260518","doi-asserted-by":"crossref","first-page":"20420188241242937","DOI":"10.1177\/20420188241242937","article-title":"Gut microbiota in MAFLD: therapeutic and diagnostic implications","volume":"15","author":"Alghamdi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R20-20260518","doi-asserted-by":"crossref","first-page":"947\u201355","DOI":"10.1093\/ibd\/izaa189","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"27","author":"Lin","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R21-20260518","doi-asserted-by":"crossref","first-page":"1937\u201344","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease","volume":"22","author":"Bessissow","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R22-20260518","doi-asserted-by":"crossref","first-page":"5676\u201386","DOI":"10.3748\/wjg.v25.i37.5676","article-title":"Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: beyond the natural history","volume":"25","author":"Magr\u00ec","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R23-20260518","doi-asserted-by":"crossref","first-page":"4535194","DOI":"10.1155\/2017\/4535194","article-title":"Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies","volume":"2017","author":"Tian","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"R24-20260518","doi-asserted-by":"crossref","first-page":"1357632","DOI":"10.3389\/fimmu.2024.1357632","article-title":"Identification and validation of hub genes expressed in ulcerative colitis with metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"R25-20260518","first-page":"802\u201314","article-title":"Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hu","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"R26-20260518","doi-asserted-by":"crossref","first-page":"1376\u201387","DOI":"10.1136\/gutjnl-2024-331914","article-title":"Heavy arch: from inflammatory bowel diseases to metabolic disorders","volume":"73","author":"Adolph","year":"2024","journal-title":"Gut"},{"key":"R27-20260518","doi-asserted-by":"crossref","first-page":"697\u2013707","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"R28-20260518","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R29-20260518","first-page":"2133\u201361","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R30-20260518","doi-asserted-by":"crossref","first-page":"k757","DOI":"10.1136\/bmj.k757","article-title":"Population attributable fraction","volume":"360","author":"Mansournia","year":"2018","journal-title":"Bmj"},{"key":"R31-20260518","first-page":"1705\u201314","article-title":"Non-alcoholic fatty liver degree and long-term risk of incident inflammatory bowel disease: a large-scale prospective cohort study","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"R32-20260518","doi-asserted-by":"crossref","first-page":"894\u2013907","DOI":"10.1111\/apt.16879","article-title":"Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"55","author":"Zamani","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-20260518","doi-asserted-by":"crossref","first-page":"1047129","DOI":"10.3389\/fnut.2022.1047129","article-title":"Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: a systematic analysis of the global burden of disease study 2019","volume":"9","author":"Wang","year":"2022","journal-title":"Front Nutr"},{"key":"R34-20260518","doi-asserted-by":"crossref","first-page":"344\u201360","DOI":"10.1007\/s44197-023-00109-0","article-title":"Global, regional, and national trends in incidence and mortality of primary liver cancer and its underlying etiologies from 1990 to 2019: results from the global burden of disease study 2019","volume":"13","author":"Cao","year":"2023","journal-title":"J Epidemiol Glob Health"},{"key":"R35-20260518","first-page":"31\u201335","article-title":"Partitioning linear trends in age-adjusted rates","volume":"11","author":"Hankey","year":"2000","journal-title":"Cancer Causes Control"},{"key":"R36-20260518","doi-asserted-by":"crossref","first-page":"e0302903","DOI":"10.1371\/journal.pone.0302903","article-title":"Trends in cancer mortality among the elderly in China, 2005-2035","volume":"19","author":"Wang","year":"2024","journal-title":"PLoS One"},{"key":"R37-20260518","doi-asserted-by":"crossref","first-page":"04093","DOI":"10.7189\/jogh.14.04093","article-title":"Global burden and prediction study of cutaneous squamous cell carcinoma from 1990 to 2030: a systematic analysis and comparison with China","volume":"14","author":"Huang","year":"2024","journal-title":"J Glob Health"},{"key":"R38-20260518","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12874-020-01133-5","article-title":"An R package for an integrated evaluation of statistical approaches to cancer incidence projection","volume":"20","author":"Knoll","year":"2020","journal-title":"BMC Med Res Meth"},{"key":"R39-20260518","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","volume":"388","author":"Stevens","year":"2016","journal-title":"Lancet"},{"key":"R40-20260518","doi-asserted-by":"crossref","first-page":"821\u201334","DOI":"10.1080\/17474124.2017.1343143","article-title":"The intestinal barrier: a fundamental role in health and disease","volume":"11","author":"Vancamelbeke","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R41-20260518","doi-asserted-by":"crossref","first-page":"1216\u201328","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol"},{"key":"R42-20260518","doi-asserted-by":"crossref","first-page":"1391\u201399","DOI":"10.1016\/j.jhep.2011.02.035","article-title":"DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH","volume":"55","author":"G\u00e4bele","year":"2011","journal-title":"J Hepatol"},{"key":"R43-20260518","doi-asserted-by":"crossref","first-page":"330\u201339","DOI":"10.1136\/gutjnl-2015-309990","article-title":"The gut microbiota and host health: a new clinical frontier","volume":"65","author":"Marchesi","year":"2016","journal-title":"Gut"},{"key":"R44-20260518","doi-asserted-by":"crossref","first-page":"41\u201350","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab"},{"key":"R45-20260518","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/nu15214507","article-title":"Systematic review and meta-analysis: prevalence of non-alcoholic fatty liver disease and liver fibrosis in patients with inflammatory bowel disease","volume":"15","author":"Navarro","year":"2023","journal-title":"Nutrients"},{"key":"R46-20260518","doi-asserted-by":"crossref","first-page":"288\u201398","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"R47-20260518","first-page":"119\u201324","article-title":"Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community","volume":"10","author":"Onyekwere","year":"2011","journal-title":"Ann Hepatol"},{"key":"R48-20260518","doi-asserted-by":"crossref","first-page":"11\u201320","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R49-20260518","doi-asserted-by":"crossref","first-page":"851\u201361","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R50-20260518","doi-asserted-by":"crossref","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"R51-20260518","doi-asserted-by":"crossref","first-page":"2215540","DOI":"10.1080\/07853890.2023.2215540","article-title":"Global, regional and national burden of orofacial clefts from 1990 to 2019: an analysis of the global burden of disease study 2019","volume":"55","author":"Wang","year":"2023","journal-title":"Ann Med"},{"key":"R52-20260518","doi-asserted-by":"crossref","first-page":"29230","DOI":"10.1038\/s41598-024-80624-7","article-title":"Author correction: global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021","volume":"14","author":"Yang","year":"2024","journal-title":"Sci Rep"},{"key":"R53-20260518","doi-asserted-by":"crossref","first-page":"e13316","DOI":"10.1111\/obr.13316","article-title":"Dietary fiber-derived short-chain fatty acids: a potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease","volume":"22","author":"Zhang","year":"2021","journal-title":"Obes Rev"},{"key":"R54-20260518","doi-asserted-by":"crossref","first-page":"1079\u201399","DOI":"10.1007\/s10198-025-01757-8","article-title":"Age, morbidity, and time to death: end-of-life expenditures on health care for the young-old population","volume":"26","author":"Torrini","year":"2025","journal-title":"Eur J Health Econ"},{"key":"R55-20260518","doi-asserted-by":"crossref","first-page":"281\u201383","DOI":"10.3109\/08880019709009499","article-title":"Immunophenotype and severity of marrow failure at diagnosis of lymphoblastic leukemia","volume":"14","author":"Holt","year":"1997","journal-title":"Pediatr Hematol Oncol"},{"key":"R56-20260518","doi-asserted-by":"crossref","first-page":"G621","DOI":"10.1152\/ajpgi.00274.2010","article-title":"Estrogen receptor-\u03b2 signaling modulates epithelial barrier function","volume":"300","author":"Looijer-van Langen","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R57-20260518","doi-asserted-by":"crossref","first-page":"2643\u201355","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between estrogen receptor-\u03b1 and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat Med"},{"key":"R58-20260518","doi-asserted-by":"crossref","first-page":"606\u201316","DOI":"10.1177\/1535370216688569","article-title":"An estrogen receptor \u03b2-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors","volume":"242","author":"Ponnusamy","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"R59-20260518","first-page":"571","article-title":"Estrogen receptor \u03b2 activation alleviates inflammatory bowel disease by suppressing NLRP3-dependent IL-1\u03b2 production in macrophages via downregulation of intracellular calcium level","volume":"57","author":"Zhu","journal-title":"J Adv Res"},{"key":"R60-20260518","doi-asserted-by":"crossref","first-page":"e0252286","DOI":"10.1371\/journal.pone.0252286","article-title":"Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: a Taiwanese retrospective cohort study","volume":"16","author":"Yen","year":"2021","journal-title":"PLoS One"},{"key":"R61-20260518","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/jcm11092623","article-title":"Hepatic steatosis and fibrosis in chronic inflammatory bowel disease","volume":"11","author":"Veltkamp","year":"2022","journal-title":"J Clin Med"},{"key":"R62-20260518","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1016\/j.cell.2024.07.019","article-title":"Stress-sensitive neural circuits change the gut microbiome via duodenal glands","volume":"187","author":"Chang","year":"2024","journal-title":"Cell"},{"key":"R63-20260518","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12889-024-21257-3","article-title":"Effects of air pollution on the development and progression of digestive diseases: an umbrella review of systematic reviews and meta-analyses","volume":"25","author":"Zhao","year":"2025","journal-title":"BMC Public Health"},{"key":"R64-20260518","doi-asserted-by":"crossref","first-page":"55\u201371","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"R65-20260518","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1038\/s41467-022-31312-5","article-title":"Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment","volume":"13","author":"Schneider","year":"2022","journal-title":"Nat Commun"},{"key":"R66-20260518","doi-asserted-by":"crossref","first-page":"1\u20139","DOI":"10.1093\/ibd\/izaa097","article-title":"Multidimensional impact of mediterranean diet on IBD patients","volume":"27","author":"Chicco","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R67-20260518","doi-asserted-by":"crossref","first-page":"2162\u201368","DOI":"10.1002\/ibd.21585","article-title":"Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease","volume":"17","author":"Long","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R68-20260518","doi-asserted-by":"crossref","first-page":"112446","DOI":"10.1016\/j.jep.2019.112446","article-title":"The therapeutic effects of stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5\u03b1-reductase type 2","volume":"250","author":"Hong","year":"2020","journal-title":"J Ethnopharmacol"},{"key":"R69-20260518","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.3390\/ma13122841","article-title":"A 33.2 W high beam quality chirped-pulse amplification-based femtosecond laser for industrial processing","volume":"13","author":"Bai","year":"2020","journal-title":"Materials (Basel)"},{"key":"R70-20260518","doi-asserted-by":"crossref","first-page":"4182\u201397","DOI":"10.1021\/acs.inorgchem.0c03576","article-title":"Using reduction kinetics to control and predict the outcome of a colloidal synthesis of noble-metal nanocrystals","volume":"60","author":"Nguyen","year":"2021","journal-title":"Inorg Chem"},{"key":"R71-20260518","doi-asserted-by":"crossref","first-page":"110944","DOI":"10.1016\/j.nut.2020.110944","article-title":"Symptoms of gluten ingestion in patients with non-celiac gluten sensitivity: a randomized clinical trial","volume":"81","author":"Moleski","year":"2021","journal-title":"Nutrition"},{"key":"R72-20260518","first-page":"274\u201383","article-title":"YINDARA-4 relieves visceral hypersensitivity in irritable bowel syndrome rats via regulation of gut microbiota and serotonin levels","volume":"2","author":"Ling","year":"2022","journal-title":"Acupunct Herb Med"},{"key":"R73-20260518","first-page":"209","article-title":"Paeoniae Radix Alba effectively attenuates Polygonum multiflorum Thunb.-induced idiosyncratic liver injury by modulating M2 macrophage polarization","volume":"4(2)","author":"Xiu","journal-title":"Acupuncture and Herbal Medicine"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:21:09Z","timestamp":1779110469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003383","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"2025-06-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}